NEW YORK, Sept. 13, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. (“Company”) (OTCQB: SVFC) announced today that it will be initiating a groundbreaking in-human clinical study to treat people who suffer from diabetic induced critical limb ischemia wounds. IntelliCell has developed a proprietary treatment methodology using its autologous (your own) cellular therapy that includes adult stem cells that have demonstrated regenerative capabilities in anecdotal studies of patients treated. According to the American Diabetes Association, there are “over 65,000 lower limb amputations performed in the United States” as a direct consequence of diabetes and hundreds of thousands of diabetes related amputations globally.
Dr. Steven Victor, Chairman and CEO of IntelliCell stated, “Diabetes is a growing problem in the United States and around the world. We hope to show that our unique autologous cellular therapy may make a contribution to those who suffer from this terrible disease and reduce the number of people that undergo amputations from non-healing wounds in their legs and other extremities.”
Robert Sexauer, VP of Clinical Development added, “Regenerative Medicine is progressing to the point whereby we can begin to truly offer personalized medicine based on each patients unique needs. IntelliCell has developed a novel treatment methodology that may impact a number of disease states with significant unmet clinical needs.”
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (AAVC’s) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology licensing agreements with technology developers, universities, and international business entities.
Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.
Contact:
IntelliCell BioSciences, Inc.
Robert J. Sexauer
Email Contact: rsexauer@intellicellbiosciences.com
(646) 576-8706
SOURCE IntelliCell BioSciences, Inc.
